We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Meiragtx Holdings Plc (MGTX) USD0.00003881

Sell:$7.68 Buy:$7.69 Change: $0.27 (3.39%)
NASDAQ:2.68%
Market closed |  Prices as at close on 26 May 2022 | Switch to live prices |
Sell:$7.68
Buy:$7.69
Change: $0.27 (3.39%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 May 2022 | Switch to live prices |
Sell:$7.68
Buy:$7.69
Change: $0.27 (3.39%)
Market closed |  Prices as at close on 26 May 2022 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MeiraGTx Holdings plc is an integrated clinical stage gene therapy company. The Company is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The Company has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.

Contact details

Address:
450 E 29th St Fl 15
NEW YORK
10016-8367
United States
Telephone:
+ ()
Website:
meiragtx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MGTX
ISIN:
KYG596651029
Market cap:
$357.69 million
Shares in issue:
44.71 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Cayman Islands
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Alexandria Forbes
    President, Chief Executive Officer, Director
  • Richard Giroux
    Chief Financial Officer, Chief Operating Officer
  • Robert Wollin
    General Counsel, Secretary
  • Stuart Naylor
    Chief Development Officer
  • Robert Zeldin
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.